Quest Diagnostics Raises 2025 Guidance

Diagnostic testing and information services provider Quest Diagnostics (NYSE:DGX) reported fiscal 2025 second-quarter results on Tuesday, July 22, that topped analysts' consensus expectations. Q2 revenue hit $2.76 billion and adjusted earnings per share (EPS) came in at $2.62. These results reflect improvements across sales, margins, and operating income, with management raising its outlook for both revenue and adjusted diluted EPS. The quarter showed a strong contribution from acquisitions, balanced by modest organic volume growth and slight pressure on revenue per requisition.Source: Quest Diagnostics. Note: Analysts' consensus estimates for the quarter provided by FactSet. YOY = Year over year. pp = percentage points. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool